Moleculin Biotech, Inc. (MBRX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 6.31 |
| Open | 6.13 |
| Day High | 6.13 |
| Day Low | 5.46 |
| 52-Week High | 315 |
| 52-Week Low | 3.22 |
| Volume | 59,094 |
| Average Volume | 69,905 |
| Market Cap | 6M |
| PE | -0.38 |
| EPS | -15.37 |
| Moving Average 50 Days | 11.3 |
| Moving Average 200 Days | 42.61 |
| Change | -0.42 |
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
GlobeNewswire Inc.
Mar 11, 2026 1:00 PM GMT
Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform featuring Walter
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
GlobeNewswire Inc.
Feb 19, 2026 1:39 PM GMT
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain ou
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
GlobeNewswire Inc.
Feb 18, 2026 1:20 PM GMT
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter